Q1 2024 · 13F-HR
TCG Crossover Management, LLCholdings as filed
Filed 2024-05-15 · accession 0001214659-24-009128
$1.26B
Reported value
33
Positions
2024-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 156944100 | CGON | CG ONCOLOGY, INC. | $156.7M | 12.4% | 3,570,206 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS, INC | $75.2M | 5.95% | 2,650,150 | Common | SOLE |
| 04635X102 | CATBUSD | ASTRIA THERAPEUTICS, INC. | $74.3M | 5.87% | 5,278,928 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $71.2M | 5.63% | 3,295,350 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $68.5M | 5.42% | 1,598,421 | Common | SOLE |
| 008064107 | — | AEROVATE THERAPEUTICS INC | $65.1M | 5.15% | 2,201,274 | Common | SOLE |
| 45720L107 | INBXUSD | INHIBRX,INC | $61.2M | 4.84% | 1,750,387 | Common | SOLE |
| 492327101 | KROS | KEROS THERAPEUTICS, INC. | $58.2M | 4.60% | 879,344 | Common | SOLE |
| 374163103 | GERN | GERON CORP | $57.4M | 4.54% | 17,391,639 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC. | $49.8M | 3.94% | 10,000,000 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX, INC. | $48.4M | 3.83% | 5,319,148 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $41.8M | 3.30% | 6,214,375 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS, INC. | $41.5M | 3.28% | 2,272,728 | Common | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS, INC. | $41.1M | 3.25% | 3,185,185 | Common | SOLE |
| 558868105 | MDGL | MADRIGAL PHARMACEUTICALS INC | $39.9M | 3.15% | 149,283 | Common | SOLE |
| 89157D105 | TRML | TOURMALINE BIO INC | $33.8M | 2.68% | 1,477,593 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $32.6M | 2.58% | 1,989,103 | Common | SOLE |
| 20451W101 | CMPS | COMPASS PATHWAYS PLC | $32.1M | 2.54% | 3,858,000 | Common | SOLE |
| 50127T109 | KURA | KURA ONCOLOGY INC | $30.4M | 2.40% | 1,423,642 | Common | SOLE |
| 87650L103 | TARS | TARSUS PHARMACEUTICALS, INC. | $28.9M | 2.28% | 793,829 | Common | SOLE |
| 00773U108 | ADVMCHF | ADVERUM BIOTECHNOLOGIES, INC. | $28.4M | 2.25% | 2,008,340 | Common | SOLE |
| 834203200 | — | SOLENO THERAPEUTIVS, INC. | $23.5M | 1.86% | 550,000 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $23.1M | 1.82% | 2,040,816 | Common | SOLE |
| 00370M103 | ABVX | Abivax SA | $15.7M | 1.24% | 1,100,000 | Common | SOLE |
| 92840H202 | — | VISTAGEN THERAPEUTICS INC | $14.1M | 1.12% | 2,676,580 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS, INC | $13.8M | 1.09% | 1,163,356 | Common | SOLE |
| 12529R107 | CCCC | C4 THERAPEUTICS, INC. | $10.4M | 0.82% | 1,276,574 | Common | SOLE |
| 29384C108 | TRDA | ENTRADA THERAPEUTICS INC | $8.3M | 0.66% | 584,955 | Common | SOLE |
| 037326105 | ANTX | AN2 Therapeutics, Inc. | $5.1M | 0.40% | 1,555,118 | Common | SOLE |
| 50015M109 | KOD | KODIAK SCIENCES INC | $4.7M | 0.37% | 899,999 | Common | SOLE |
| 92332V107 | VTYXUSD | VENTYX BIOSCIENCES, INC | $4.5M | 0.35% | 815,724 | Common | SOLE |
| 640268108 | NKTREUR | NEKTAR THERAPEUTICS | $3.7M | 0.30% | 4,000,000 | Common | SOLE |
| 12674W109 | CABA | CABALETTA BIO, INC | $1.5M | 0.12% | 86,795 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.